story of the week
NBTXR3 Plus Radiotherapy vs Radiotherapy Alone in Patients With Locally Advanced Soft Tissue Sarcoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
NBTXR3, a First-in-Class Radioenhancer Hafnium Oxide Nanoparticle, Plus Radiotherapy Versus Radiotherapy Alone in Patients With Locally Advanced Soft-Tissue Sarcoma (Act.In.Sarc): A Multicentre, Phase 2-3, Randomised, Controlled Trial
Lancet Oncol 2019 Jul 08;[EPub Ahead of Print], S Bonvalot, PL Rutkowski, J Thariat, S Carrère, A Ducassou, MP Sunyach, P Agoston, A Hong, A Mervoyer, M Rastrelli, V Moreno, RK Li, B Tiangco, AC Herraez, A Gronchi, L Mangel, T Sy-Ortin, P Hohenberger, T de Baère, A Le Cesne, S Helfre, E Saada-Bouzid, A Borkowska, R Anghel, A Co, M Gebhart, G Kantor, A Montero, HH Loong, R Vergés, L Lapeire, S Dema, G Kacso, L Austen, L Moureau-Zabotto, V Servois, E Wardelmann, P Terrier, AJ Lazar, JVMG Bovée, C Le Péchoux, Z PapaiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.